GlassVC
Tom Woiwode

Tom Woiwode

Managing Director · Versant Ventures

Managing Director

Tom Woiwode has worked with Versant Ventures since 2002 in operational and investment roles and was promoted to Managing Director in 2014. He served as start-up CBO for Amira, Synosia and Flexion and as COO of Okairos, leading its acquisition process with GSK, and has since led multiple investments that reached liquidity. He was previously a medicinal chemist at XenoPort and earned his Ph.D. in chemistry from Stanford.

Board seats

99 current

· PUBLIC SOURCES

Credited hits

13

· PUBLIC SOURCES

Midas years

No public record

LAST CHECKED NOV 2026

Founder rating

No public record

LAST CHECKED NOV 2026

Maintained from public sources. Not claimed. If you're Tom Woiwode, you can claim this profile.

Claim this profileHow claiming works

Claiming verifies identity and affiliation. It does not permit editing reviews, scores, or cited facts.

Track record

Credited deals only — Tom Woiwode is named in a public source as investor, lead, or board member on these deals. This is not a complete investment history, and absence here is not evidence of absence.
  • Flexion Therapeuticsipo

    His Versant bio: he was start-up CBO for Flexion (2014 IPO).

    Source: versantventures.com

  • CRISPR Therapeuticsipo

    His Versant bio: since becoming Managing Director he assumed the lead role in investments that reached liquidity including Crispr (2016 IPO).

    Source: versantventures.com

  • Audentes Therapeuticsipo

    His Versant bio lists Audentes (2016 IPO) among lead-role investments that reached liquidity.

    Source: versantventures.com

  • Crinetics Pharmaceuticalsipo

    His Versant bio lists Crinetics (2018 IPO) among lead-role investments that reached liquidity.

    Source: versantventures.com

  • Okairosacquired

    His Versant bio: as COO of Okairos he led the process that culminated in the acquisition by GSK.

    Source: versantventures.com

  • Vividion Therapeuticsacquired

    His Versant bio lists Vividion (sale) among lead-role investments that reached liquidity.

    Source: versantventures.com

  • Amira Pharmaceuticalsacquired

    Start-up CBO; firm bio marks it a sale.

    Source: versantventures.com

  • Synosia Therapeuticsacquired

    Start-up CBO; firm bio marks it a sale.

    Source: versantventures.com

  • Gritstone bioipo

    Firm bio lists 2018 IPO among his lead-role investments.

    Source: versantventures.com

  • Jecure Therapeuticsacquired

    Firm bio marks it a sale among his lead-role investments.

    Source: versantventures.com

  • Therachonacquired

    Firm bio marks it a sale among his lead-role investments.

    Source: versantventures.com

  • Aligos Therapeuticsipo

    Firm bio lists 2020 IPO among his lead-role investments.

    Source: versantventures.com

  • Passage Bioipo

    Firm bio lists 2020 IPO among his lead-role investments.

    Source: versantventures.com

Board seats

Current board seats · 9

Success signals

Forbes Midas List

No public record

Not listed.

Reputation

No reputation score — basis not established for this investor.

No reputation sources on file yet.

Suggest a source

Contact

Published sources only

Published contact details collected from public sources. Not a referral, and not an introduction.

Published contact

Published sources only

GlassVC lists only contact information the firm or its sources have published. We do not list personal emails, direct lines, or private addresses.

Claimed profiles can replace or remove contact details.

What founders say

Founder-submitted · Verified identity and relationship

No founder reviews yet

Be the first founder to share your experience with Tom Woiwode. Reviews come from founders whose identity and relationship have been verified.

Write the first review
Reviews of Versant Ventures (0) →

Firm-level reviews are not attributed to Tom Woiwode.

Methodology

This profile carries no tier: tier belongs to the firm and is shown only via the linked firm name — never inherited onto a person.

Credited deals, board seats, Midas years and reputation links are carried per investor in the catalog, each item with the public source it was credited from, linked from the sections above. Fields with no sourced record render their honest null states, and every published field traces to the catalog record listed below. Review dimension scores appear only at three or more reviews.

Corrections with a source: Suggest a correction.

Source record 1

  1. [1]

    DATABASE · GlassVC catalog — Catalog record for Tom Woiwode — provenance: GlassVC catalog

    CATALOG SOURCE FIELD · LAST CHECKED NOV 2026

    ↩ cites: Title · Firm · Type · Bio · Location · Focus · Credited deals · Board seats

EVERY FIGURE ON THIS PAGE IS TRACEABLE TO THE CATALOG RECORD ABOVE · LAST CHECKED NOV 2026